Biomarkers

Therapy Areas

Drug Classes

Therapy Areas

All Sessions

Resectable NSCLC

Advanced NSCLC

SCLC

Biomarkers

Drug Classes

Targeted Therapies

Immunotherapies

ADCs

All

FEATURED

ILCS

Webinars

Articles

Industry Sponsored

Featured Sessions

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

From Our Annual Summit

ILCS Sessions

Members only

Sep 26 2025

ILCS 2025

Biomarkers

Cutting-Edge Diagnostic Techniques and Emerging Biomarkers

} 24 min

Advancements in Diagnostics: Current Guidelines and Emerging Tests

} 20 min

A. Schultheis

Expert Insights

Webinars

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

The Reading Room

Articles & Research

Aug 07 2026

TARGETED THERAPIES

Advanced NSCLCBiomarkersTargeted Therapies

EGFR amplification at baseline marks shorter time on first-line osimertinib, in exon 19 deletions but not L858R

B. Ricciuti

Aug 07 2026

ADCs

Advanced NSCLCBiomarkersADCs

EVOKE-01 biomarker analysis: Trop-2 staining did not pick out who does better on sacituzumab govitecan than docetaxel

G. Mountzios

Industry Sponsored

Featured Sessions

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

From Our Annual Summit

ILCS Sessions

Members only

Sep 26 2025

ILCS 2025

Biomarkers

Cutting-Edge Diagnostic Techniques and Emerging Biomarkers

} 24 min

Advancements in Diagnostics: Current Guidelines and Emerging Tests

} 20 min

A. Schultheis

Expert Insights

Webinars

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

The Reading Room

Articles & Research

Aug 07 2026

TARGETED THERAPIES

Advanced NSCLCBiomarkersTargeted Therapies

EGFR amplification at baseline marks shorter time on first-line osimertinib, in exon 19 deletions but not L858R

B. Ricciuti

Aug 07 2026

ADCs

Advanced NSCLCBiomarkersADCs

EVOKE-01 biomarker analysis: Trop-2 staining did not pick out who does better on sacituzumab govitecan than docetaxel

G. Mountzios

Manage Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options
Manage services
Manage {vendor_count} vendors
Read more about these purposes

View preferences

{title}
{title}
{title}